

CANADIAN GUIDELINES ON SEXUALLY TRANSMITTED INFECTIONS (2008 UPDATE)

V – MANAGEMENT AND TREATMENT OF SPECIFIC INFECTIONS

GENITAL HUMAN PAPILLOMAVIRUS (HPV) INFECTIONS (January 2008)

References

1. Mu-oz N, Bosch FX, de Sanjosé S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. *N Engl J Med* 2003;348:518–527.
2. Franco EL, Duarte-Franco E, Ferenczy A. Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection. *CMAJ* 2001;164:1017–1025.
3. Koutsky LA, Galloway DA, Holmes KK. Epidemiology of genital human papillomavirus infection. *Epidemiol Rev* 1988;10:122–163.
4. Richardson H, Franco E, Pintos J, Bergeron J, Arella M, Tellier P. Determinants of low-risk and high-risk cervical human papillomavirus infections in Montreal University students. *Sex Transm Dis* 2000;27:79–86.
5. Richardson H, Kelsall G, Tellier P, et al. The natural history of type-specific human papillomavirus infections in female university students. *Cancer Epidemiol Biomarkers Prev* 2003;12:485–490.
6. Young T, McNichol P, Beauvais J. Factors associated with human papillomavirus infection detected by polymerase chain reaction among urban Canadian aboriginal and non-aboriginal women. *Sex Transm Dis* 1997;24:293–298.
7. Sellors JW, Mahony JB, Kaczorowski J, et al. Prevalence and predictors of human papillomavirus infection in women in Ontario, Canada. Survey of HPV in Ontario Women (SHOW) Group. *CMAJ* 2000;163:503–508.
8. Sellors JW, Karwalajtys TL, Kaczorowski JA, et al. Prevalence of infection with carcinogenic human papillomavirus among older women. *CMAJ* 2002;167:871–873.
9. Healey SM, Aronson KJ, Mao Y, et al. Oncogenic human papillomavirus infection and cervical lesions in aboriginal women of Nunavut, Canada. *Sex Transm Dis* 2001;28:694–700.
10. Burk RD, Kelly P, Feldman J, et al. Declining prevalence of cervicovaginal human papillomavirus infection with age is independent of other risk factors. *Sex Transm Dis* 1996;23:333–341.
11. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. *N Engl J Med* 1998;338:423–428.
12. Jay N, Moscicki AB. Human papillomavirus infections in women with HIV disease: prevalence, risk, and management. *AIDS Read* 2000;10:659–668.
13. International Agency for Research on Cancer. *Cervix Cancer Screening*. IARC Handbooks of Cancer Prevention, vol. 10. Oxford: Oxford University Press, 2005.
14. Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. *Am J Epidemiol* 2000;151:1158–1171.
15. Thomas KK, Hughes JP, Kuypers JM, et al. Concurrent and sequential acquisition of different genital human papillomavirus types. *J Infect Dis* 2000;182:1097–1102.
16. Liaw KL, Hildesheim A, Burk RD, et al. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. *J Infect Dis* 2001;183:8–15.

17. Rousseau MC, Pereira JS, Prado JC, Villa LL, Rohan TE, Franco EL. Cervical coinfection with human papillomavirus (HPV) types as a predictor of acquisition and persistence of HPV infection. *J Infect Dis* 2001;184:1508–1517.
18. SyrjŠnen S. HPV infections in children. *Papillomavirus Rep* 2003;14:93–109.
19. Manhart LE, Koutsky LA. Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis. *Sex Transm Dis* 2002;29:725–735.
20. Koutsky LA, Holmes KK, Critchlow CW, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. *N Engl J Med* 1992; 327:1272–1278.
21. International Agency for Research on Cancer Working Group. Human papillomaviruses (HPV). *IARC Monographs* 1995;64.
22. Schlecht NF, Kulaga S, Robitaille J, et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. *JAMA* 2001;286:3106–3114.
23. Moscicki AB, Hills N, Shiboski S, et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. *JAMA* 2001;285:2995–3002.
24. Sigurdsson K. The Icelandic and Nordic cervical screening programs: trends in incidence and mortality rates through 1995. *Acta Obstet Gynecol Scand* 1999;78:478–485.
25. Nieminen P, Kallio M, Anttila A, Hakama M. Organised vs. spontaneous Pap-smear screening for cervical cancer: a case-control study. *Int J Cancer* 1999;83:55–58.
26. Parkin DM, Nguyen-Dinh X, Day NE. The impact of cervical screening on the incidence of cervical cancer in England and Wales. *Br J Obstet Gynaecol* 1985;92:150–157.
27. Van Ranst MA, Tachezy R, Delius H, Burk RD. Taxonomy of the human papillomaviruses. *Papillomavirus Rep* 1993;4:61.
28. Noorani HZ, Brown A, Skidmore B, Stuart GCE. Liquid-based cytology and human papillomavirus testing in cervical cancer screening. Ottawa, ON: Canadian Coordinating Office for Health Technology Assessment; 2003. Technology Report No. 40.
29. ACOG Committee on Practice Bulletins. ACOG Practice Bulletin: clinical management guidelines for obstetrician-gynecologists. Number 45, August 2003. Cervical cytology screening (replaces committee opinion 152, March 1995). *Obstet Gynecol* 2003;102:417–427.
30. Sasieni P, Adams J, Cuzick J. Benefits of cervical screening at different ages: evidence from the UK audit of screening histories. *Br J Cancer* 2003;89:88–93.
31. Anttila A, Ronco G, Clifford G, et al. Cervical cancer screening programmes and policies in 18 European countries. *Br J Cancer* 2004;91:935–941.
32. Cervical Cancer Prevention Network. *Programmatic Guidelines for Screening for Cancer of the Cervix in Canada*. Ottawa, ON: Health Canada and the Society of Obstetricians and Gynecologists of Canada; 1998.
33. Health Canada. *Cervical Cancer Screening in Canada: 1998 Surveillance Report*. Ottawa, ON: Health Canada; 2002.
34. Hawes SE, Critchlow CW, Faye Niang MA, et al. Increased risk of high-grade cervical squamous intraepithelial lesions and invasive cervical cancer among African women with human immunodeficiency virus type 1 and 2 infections. *J Infect Dis* 2003;188:555–563.
35. Paterson ME, Peel KR, Joslin CA. Cervical smear histories of 500 women with invasive cancer in Yorkshire. *BMJ* 1984;289:896–898.
36. Martin-Hirsch P, Lilford R, Jarvis G, Kitchener HC. Efficacy of cervical-smear collection devices: a systematic review and meta-analysis. *Lancet* 1999;354:1763–1770.
37. NCI Bethesda System 2001. 2001 terminology. Available at: <http://bethesda2001.cancer.gov/terminology.html>. Accessed January 5, 2006.

38. Arbyn M, Buntinx F, Van Ranst M, Paraskevaidis E, Martin-Hirsch P, Dillner J. Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. *J Natl Cancer Inst* 2004;96:280–293.
39. Stuart G, Taylor G, Bancej CM, et al. Report of the 2003 Pan-Canadian Forum on Cervical Cancer Prevention and Control. *J Obstet Gynecol Can* 2004;26:1004–1014.
40. Wright TC Jr, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ; ASCCP-Sponsored Consensus Conference. 2001 consensus guidelines for the management of women with cervical cytological abnormalities. *JAMA* 2002;287:2120–2129.
41. Sexually transmitted disease guidelines 2002. Centers for Disease Control and Prevention. *MMWR Recomm Rep* 2002;51(RR-6):1–78.
42. Chao A, Lin CT, Hsueh S, et al. Usefulness of human papillomavirus testing in the follow-up of patients with high-grade cervical intraepithelial neoplasia after conization. *Am J Obstet Gynecol* 2004;190:1046–1051.
43. von Krogh G, Lacey CJ, Gross G, Barrasso R, Schneider A. European course on HPV associated pathology: guidelines for primary care physicians for the diagnosis and management of anogenital warts. *Sex Transm Infect* 2000;76:162–168.
44. Tyring SK, Arany I, Stanley MA, et al. A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod. *J Infect Dis* 1998;178:551–555.
45. Kirby P, Dunne A, King DH, Corey L. Double-blind randomized clinical trial of self-administered podofilox solution vehicle in the treatment of genital warts. *Am J Med* 1990; 88:465–470.
46. Simmons PD, Langlet F, Thin RN. Cryotherapy versus electrocautery in the treatment of genital warts. *Br J Vener Dis* 1981;57:273–274.
47. Godley MJ, Bradbeer CS, Gellan M, Thin RN. Cryotherapy compared with trichloroacetic acid in treating genital warts. *Genitourin Med* 1987;63:390–392.
48. Abdullah AN, Walzman M, Wade A. Treatment of external genital warts comparing cryotherapy (liquid nitrogen) and trichloroacetic acid. *Sex Transm Dis* 1993;20:344–345.
49. Gross GE, Barasso R, eds. *Human Papillomavirus Infection: A Clinical Atlas*. Wiesbaden: Ullstein Mosby; 1997.
50. Sarfati D, Cox B, Jones RW, Sopoaga T, Rimeme C, Paul C. National audit of women with abnormal cervical smears in New Zealand. *Aust N Z J Obstet Gynaecol* 2003;43:152–156.
51. Peterson NB, Han J, Freund KM. Inadequate follow-up for abnormal Pap smears in an urban population. *J Natl Med Assoc* 2003;95:825–832.
52. Gage JC, Ferreccio C, Gonzales M, Arroyo R, Huivin M, Robles SC. Follow-up care of women with an abnormal cytology in a low-resource setting. *Cancer Detect Prev* 2003;27: 466–471.